Posted by undopaminergic on January 20, 2020, at 9:05:16
In reply to Re: psilocybin from magic mushrooms, posted by linkadge on January 20, 2020, at 7:45:05
> We sorely need treatments with different mechanisms of action.
Very much agreed. Psychedelics are interesting, but the class of drugs that I'm missing most from the market is kappa-opioid receptor antagonists (or inverse agonists).
> We don't need another 'me too' reuptake inhibitor.
>I think a good addition would be a dopamine reuptake inhibitor (including triple reuptake inhibitors) that does not have a "(psycho)stimulant" reputation. Ie. a drug that like bupropion is known as an "antidepressant".
-undopaminergic
poster:undopaminergic
thread:1108097
URL: http://www.dr-bob.org/babble/20200104/msgs/1108104.html